## As Passed by the House

# **133rd General Assembly**

Regular Session 2019-2020

Am. S. B. No. 263

#### **Senator Hackett**

Cosponsors: Senators Maharath, Wilson, Craig, Thomas, Antonio, Kunze, Schuring, Blessing, Coley, Dolan, Fedor, Gavarone, Hoagland, Huffman, M., Huffman, S., Johnson, Lehner, Manning, McColley, O'Brien, Roegner, Rulli, Schaffer, Sykes, Yuko Representatives Clites, Koehler, Lanese, Liston, Russo, Strahorn, Sweeney, West

### A BILL

То	amend sections 5164.751 and 5167.01 and to enact	1
	sections 3902.50, 3902.51, 4729.49, and 5167.123	2
	of the Revised Code to prohibit a pharmacy	3
	benefit manager from taking certain actions with	4
	respect to reimbursements made to health care	5
	providers that participate in the federal 340B	6
	Drug Pricing Program.	7

#### BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

<b>Section 1.</b> That sections 5164.751 and 5167.01 be amended	8	
and sections 3902.50, 3902.51, 4729.49, and 5167.123 of the	9	
Revised Code be enacted to read as follows:	10	
Sec. 3902.50. As used in this section and section 3902.51	11	
of the Revised Code:		
(A) "340B covered entity" and "third-party administrator"	13	
have the same meanings as in section 5167.01 of the Revised	14	
Code.	15	

(B) "Health plan issuer" has the same meaning as in	16
section 3922.01 of the Revised Code.	17
(C) "Terminal distributor of dangerous drugs" has the same	18
meaning as in section 4729.01 of the Revised Code.	19
	-
Sec. 3902.51. (A) On and after the effective date of this	20
section, a contract entered into between a health plan issuer,	21
including a third-party administrator, and a 340B covered entity	
shall not contain any of the following provisions:	
(1) A reimbursement rate for a prescription drug that is	24
less than the national average drug acquisition cost rate for	25
that drug as determined by the United States centers for	26
medicare and medicaid services, measured at the time the drug is	27
administered or dispensed, or, if no such rate is available at	28
that time, a reimbursement rate that is less than the wholesale	29
acquisition cost of the drug, as defined in 42 U.S.C. 1395w-	30
3a(c)(6)(B);	31
	2.0
(2) A dispensing fee reimbursement amount that is less	32
than the reimbursement amount provided to a terminal distributor	33
of dangerous drugs under section 5164.753 of the Revised Code;	34
(3) A fee that is not imposed on a health care provider	35
that is not a 340B covered entity;	36
(4) A fee amount that exceeds the fee amount for a health	37
care provider that is not a 340B covered entity.	38
(B) No health plan issuer or third-party administrator	39
making payments pursuant to a health benefit plan shall	40
discriminate against a 340B covered entity in a manner that	41
prevents or interferes with an enrollee's choice to receive a	
prescription drug from a 340B covered entity or its contracted	
pharmacies.	

(C) Any provision of a contract entered into between a	45
health plan issuer and a 340B covered entity that is contrary to	46
division (A) of this section is unenforceable and shall be	47
replaced with the dispensing fee or reimbursement rate that	48
applies for health care providers that are not 340B covered	49
entities.	50
Sec. 4729.49. (A) As used in this section, "340B covered	51
entity," "medicaid managed care organization," and "third-party	52
administrator" have the same meanings as in section 5167.01 of	53
the Revised Code.	54
(B) A contract between a terminal distributor of dangerous	55
drugs and a 340B covered entity shall require the terminal	56
distributor to comply with division (C) of this section.	57
(C) When paying a 340B covered entity for a dangerous drug	58
dispensed to a patient, a terminal distributor shall pay to the	59
340B covered entity the full reimbursement amount the terminal	60
distributor receives from the patient and the patient's health	61
insurer, including a third-party administrator or medicaid	62
managed care organization, except that the terminal distributor	63
may deduct from the full reimbursement amount a fee agreed on in	64
writing by the terminal distributor and the 340B covered entity.	65
Sec. 5164.751. (A) As used in this section, "state maximum	66
allowable cost" means the per unit amount the medicaid program	67
pays a terminal distributor of dangerous drugs for a prescribed	68
drug included in the state maximum allowable cost program	69
established under division (B) of this section. "State maximum	70
allowable cost" excludes dispensing fees and copayments,	71
coinsurance, or other cost-sharing charges, if any.	72
(B) The Subject to section 5167.123 of the Revised Code,	73

Am. S. B. No. 263

Page 4

101

in section 5160.01 of the Revised Code.	
(E) (F) "Emergency services" has the same meaning as in	103
the "Social Security Act," section 1932(b)(2), 42 U.S.C. 1396u-	104
2(b)(2).	
(F) (G) "Enrollee" means a medicaid recipient who	106 107
participates in the care management system and enrolls in a	
medicaid MCO plan.	108
(G) (H) "ICDS participant" has the same meaning as in	109
section 5164.01 of the Revised Code.	
(H) (I) "Medicaid managed care organization" means a	111
managed care organization under contract with the department of	
medicaid pursuant to section 5167.10 of the Revised Code.	
(I) (J) "Medicaid MCO plan" means a plan that a medicaid	114
managed care organization, pursuant to its contract with the	
department of medicaid under section 5167.10 of the Revised	116
Code, makes available to medicaid recipients participating in	117
the care management system.	118
(J) (K) "Medicaid waiver component" has the same meaning	119
as in section 5166.01 of the Revised Code.	120
$\frac{K}{K}$ "Network provider" has the same meaning as in 42	121
C.F.R. 438.2.	122
(L) (M) "Nursing facility services" has the same meaning	123
as in section 5165.01 of the Revised Code.	124
(M) (N) "Part B drug" means a drug or biological described	125
in section 1842(o)(1)(C) of the "Social Security Act," 42 U.S.C.	126
1395u(o)(1)(C).	
$\frac{(N)-(O)}{(N)}$ "Pharmacy benefit manager" has the same meaning as	128

the national average drug acquisition cost rate for that drug as

determined by the United States centers for medicare and

155

156

medicaid services, measured at the time the drug is administered	157
or dispensed, or, if no such rate is available at that time, a	158
reimbursement rate that is less than the wholesale acquisition	159
<pre>cost of the drug, as defined in 42 U.S.C. 1395w-3a(c)(6)(B);</pre>	160
(2) A fee that is not imposed on a health care provider	161
that is not a 340B covered entity;	
(3) A fee amount that exceeds the amount for a health care	163
provider that is not a 340B covered entity.	164
(B) The organization, or its contracted third-party	165
administrators, shall not discriminate against a 340B covered	166
entity in a manner that prevents or interferes with a medicaid	167
recipient's choice to receive a prescription drug from a 340B	
covered entity or its contracted pharmacies.	
(C) Any provision of a contract entered into between the	170
organization and a 340B covered entity that is contrary to	
division (A) of this section is unenforceable and shall be	172
replaced with the dispensing fee or payment rate that applies	173
for health care providers that are not 340B covered entities.	174
Section 2. That existing sections 5164.751 and 5167.01 of	175
the Revised Code are hereby repealed	176